Oscar Zhang
Principal @ Qiming Venture Partners
Shanghai, China
Oscar Zhang is a Principal of Qiming Venture Partners, focusing on investments in healthcare sector.Oscar joined Qiming Venture Partners in 2015. Prior to joining Qiming Venture Partners, Oscar worked at WI Harper as Senior Investment Associate. Before that, he worked at China eCapital Corporation (now CEC Capital Group) as Associate.Oscar hasbeen named by PEDaily, a media outlet under Zero2IPO Group, as one of the "Forty Fancy Future Top 40 Investors". Oscar has also been named by CYZONE as one of the 'Top 40 under 40' investors in 2019.Oscar holds an MSc degree in Medical Physics from the University of Edinburgh, and an MSc degree in Risk Management and Financial Engineering from Imperial College London Business School. He also earned a BEng degree in Biomedical Engineering from Tsinghua University.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 63%
Last updated:
For AI agents: llms.txt
Industries Oscar Zhang invests in
Stages Oscar Zhang invests in
Countries Oscar Zhang invests in
Investment Focus
Industry
- Health Care 9 (33%)
- Medical 7 (26%)
- Manufacturing 6 (22%)
- Medical Device 3 (11%)
- Artificial Intelligence 2 (7%)
Stage
- Series B 9 (33%)
- Series A 7 (26%)
- Series C 2 (7%)
- Series D 2 (7%)
- Series E 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Ronghe Medical
|
Ronghe Medical is a medical device manufacturer specializing in the design, research and development, production, and sales of high-end medical device systems based on advanced energy ablation technology platforms, delivering innovative therapeutic solutions that enhance clinical precision, improve patient outcomes, and support a wide range ofmedical applications. | $14.1M / Series B / Nov 18, 2025 | |
Singular Medical
|
Singular Medical is a technology company specializing in R&D and industrialization of cardiac rhythm management (CRM) products. The company builds a complete technical platform and is a supplier of full line of CRM products, which provides a complete range of solutions, from detection to follow-up for large amounts of cardiac patients. | $20.7M / Series C / Mar 12, 2025 | |
Xinzeyuan Medical
|
Xinzeyuan Medical is a manufacturer of key precision components and medical endoscope consumables. | $10.2M / Series B / Jan 20, 2025 | |
|
Xinzeyuan Medical
|
Xinzeyuan Medical is a manufacturer of key precision components and medical endoscope consumables. | $14.3M / Series B / Jul 08, 2024 | |
Ruining Bio
|
Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine. | $8.5M / Series B / Jan 24, 2024 | |
Shennapsi Artificial Intelligence Technology
|
Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterolmonitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology. | Series A / Oct 29, 2023 | |
Saints Sages Medical
|
Saints Sages Medical is engaged in the production and sales of minimally invasive surgical medical devices. They have several energy device products that are widely used in minimally invasive surgery, hepatobiliary surgery, gynecology, urology, thoracic surgery, and other departments. Saints Sages closely monitors clinical needs and develops moreinnovative minimally invasive surgical devices to serve global patients, relying on a professional research and development team and years of the clinical transformation experience. | Series B / Aug 21, 2023 | |
|
Singular Medical
|
Singular Medical is a technology company specializing in R&D and industrialization of cardiac rhythm management (CRM) products. The company builds a complete technical platform and is a supplier of full line of CRM products, which provides a complete range of solutions, from detection to follow-up for large amounts of cardiac patients. | Series B / Jan 06, 2023 | |
Insyce
|
Inces is an innovative high-tech enterprise focusing on bio-separation technology. | $21.8M / Series B / Jan 04, 2023 | |
|
Fitlens
|
Fitlens | Series B / Dec 12, 2022 | |
| See all 27 investments → | |||
Co-Investors
About Qiming Venture Partners
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Qiming Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Grace Lee
Partner & CFO
|
|||
Jinda Gao
Principal
|
|||
|
Oscar Zhang
Principal
|
|||
Shiyu Wang
Partner
|
|||
Alexander Sinclair-Wilson
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Oscar Zhang invest in?
Oscar Zhang invests primarily in Health Care, Medical and Manufacturing startups, most often at Series B and Series A stage. Most of the 27 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Oscar Zhang last invest?
The most recent investment recorded for Oscar Zhang closed in Nov 2025. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
